Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 May;58(5):1269–1272. doi: 10.1128/iai.58.5.1269-1272.1990

Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton protease.

T Oda 1, Y Kojima 1, T Akaike 1, S Ijiri 1, A Molla 1, H Maeda 1
PMCID: PMC258619  PMID: 1691142

Abstract

The effects of the 56-kilodalton protease (56K protease) from Serratia marcescens on complement-derived chemotactic activity were examined. Fresh human serum was incubated with zymosan to produce C5a. This activated serum was then incubated with various concentrations of 56K protease, and the chemotactic activity of mouse peritoneal exudate polymorphonuclear leukocytes (PMN) and macrophages was evaluated. A significant dose-dependent decrease of chemotactic activity was observed after protease treatment. Furthermore, treatment of human recombinant C5a with 56K protease at a dose of 1.0 microgram/ml resulted in a complete loss of chemotactic activity. When the living bacteria of the virulent strain, which produced about 10 times more protease than did the less virulent strain, were injected intraperitoneally into mice, the magnitude of infiltration of polymorphonuclear leukocytes into the peritoneal cavity was much lower than that caused by the less virulent strain. Because complement-dependent chemotactic activity is an initial response to bacterial infection, these results suggest indirect pathogenic functions of serratial proteases that suppress chemotactic activity.

Full text

PDF
1269

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akaike T., Molla A., Ando M., Araki S., Maeda H. Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice. J Virol. 1989 May;63(5):2252–2259. doi: 10.1128/jvi.63.5.2252-2259.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  3. Hill H. R., Bohnsack J. F., Morris E. Z., Augustine N. H., Parker C. J., Cleary P. P., Wu J. T. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol. 1988 Nov 15;141(10):3551–3556. [PubMed] [Google Scholar]
  4. Imber M. J., Pizzo S. V. Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem. 1981 Aug 10;256(15):8134–8139. [PubMed] [Google Scholar]
  5. Kamata R., Matsumoto K., Okamura R., Yamamoto T., Maeda H. The serratial 56K protease as a major pathogenic factor in serratial keratitis. Clinical and experimental study. Ophthalmology. 1985 Oct;92(10):1452–1459. doi: 10.1016/s0161-6420(85)33855-1. [DOI] [PubMed] [Google Scholar]
  6. Kamata R., Yamamoto T., Matsumoto K., Maeda H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect Immun. 1985 Jun;48(3):747–753. doi: 10.1128/iai.48.3.747-753.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lyerly D. M., Kreger A. S. Importance of serratia protease in the pathogenesis of experimental Serratia marcescens pneumonia. Infect Immun. 1983 Apr;40(1):113–119. doi: 10.1128/iai.40.1.113-119.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lyerly D., Gray L., Kreger A. Characterization of rabbit corneal damage produced by Serratia keratitis and by a serratia protease. Infect Immun. 1981 Sep;33(3):927–932. doi: 10.1128/iai.33.3.927-932.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maeda H., Molla A., Oda T., Katsuki T. Internalization of serratial protease into cells as an enzyme-inhibitor complex with alpha 2-macroglobulin and regeneration of protease activity and cytotoxicity. J Biol Chem. 1987 Aug 15;262(23):10946–10950. [PubMed] [Google Scholar]
  10. Maeda H., Molla A. Pathogenic potentials of bacterial proteases. Clin Chim Acta. 1989 Dec 15;185(3):357–367. doi: 10.1016/0009-8981(89)90226-x. [DOI] [PubMed] [Google Scholar]
  11. Maki D. G., Hennekens C. G., Phillips C. W., Shaw W. V., Bennett J. V. Nosocomial urinary tract infection with Serratia marcescens: an epidemiologic study. J Infect Dis. 1973 Nov;128(5):579–587. doi: 10.1093/infdis/128.5.579. [DOI] [PubMed] [Google Scholar]
  12. Matsumoto K., Maeda H., Takata K., Kamata R., Okamura R. Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958. J Bacteriol. 1984 Jan;157(1):225–232. doi: 10.1128/jb.157.1.225-232.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Matsumoto K., Yamamoto T., Kamata R., Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem. 1984 Sep;96(3):739–749. doi: 10.1093/oxfordjournals.jbchem.a134892. [DOI] [PubMed] [Google Scholar]
  14. Molla A., Akaike T., Maeda H. Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens. Infect Immun. 1989 Jun;57(6):1868–1871. doi: 10.1128/iai.57.6.1868-1871.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Molla A., Kagimoto T., Maeda H. Cleavage of immunoglobulin G (IgG) and IgA around the hinge region by proteases from Serratia marcescens. Infect Immun. 1988 Apr;56(4):916–920. doi: 10.1128/iai.56.4.916-920.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Molla A., Matsumoto K., Oyamada I., Katsuki T., Maeda H. Degradation of protease inhibitors, immunoglobulins, and other serum proteins by Serratia protease and its toxicity to fibroblast in culture. Infect Immun. 1986 Sep;53(3):522–529. doi: 10.1128/iai.53.3.522-529.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Molla A., Matsumura Y., Yamamoto T., Okamura R., Maeda H. Pathogenic capacity of proteases from Serratia marcescens and Pseudomonas aeruginosa and their suppression by chicken egg white ovomacroglobulin. Infect Immun. 1987 Oct;55(10):2509–2517. doi: 10.1128/iai.55.10.2509-2517.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Molla A., Oda T., Maeda H. Different binding kinetics of Serratia 56K protease with plasma alpha 2-macroglobulin and chicken egg white ovomacroglobulin. J Biochem. 1987 Jan;101(1):199–205. doi: 10.1093/oxfordjournals.jbchem.a121892. [DOI] [PubMed] [Google Scholar]
  19. Molla A., Yamamoto T., Akaike T., Miyoshi S., Maeda H. Activation of hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem. 1989 Jun 25;264(18):10589–10594. [PubMed] [Google Scholar]
  20. Molla A., Yamamoto T., Maeda H. Characterization of 73 kDa thiol protease from Serratia marcescens and its effect on plasma proteins. J Biochem. 1988 Oct;104(4):616–621. doi: 10.1093/oxfordjournals.jbchem.a122521. [DOI] [PubMed] [Google Scholar]
  21. Oda T., Maeda H. A new simple fluorometric assay for phagocytosis. J Immunol Methods. 1986 Apr 17;88(2):175–183. doi: 10.1016/0022-1759(86)90004-9. [DOI] [PubMed] [Google Scholar]
  22. Ueda K., Kawaguchi T., Okamoto T., Kambara T. The chemical mediation of delayed hypersensitivity skin reactions: III. Purification and characterization of a precursor protein for macrophage-chemotactic factor in normal guinea pig plasma. Am J Pathol. 1982 Sep;108(3):291–298. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES